組織工学による皮膚代替物市場：製品、用途、最終用途別-2025-2030年の世界予測

組織工学による皮膚代替物市場は、2023年に11億2,000万米ドルと評価され、2024年には12億5,000万米ドルに達すると予測され、CAGR 12.65％で成長し、2030年には25億8,000万米ドルに達すると予測されています。

組織工学による皮膚代替物は再生医療におけるダイナミックなセクターであり、火傷、慢性創傷、外科的再建により皮膚の代替を必要とする人々に高度なソリューションを提供します。これらの代用品の範囲には、生物学的または合成材料を統合し、治癒を促進し、患者の組織と統合する、合成、生合成、生きた皮膚構築物が含まれます。これらの製品の必要性は、慢性創傷や熱傷の増加、人口の高齢化、より効果的で持続可能な治療を可能にするバイオテクノロジーの進歩によってもたらされています。用途は創傷治療、皮膚科、形成外科などの医療分野に広がり、回復時間の短縮と患者の転帰の改善によってヘルスケアシステムに大きな利益をもたらしています。最終用途には、病院、火傷センター、長期介護施設などが含まれ、このような代用品が救命につながることもあります。

市場成長は、製品の有効性と個々の患者のニーズへの適応性を高める3Dバイオプリンティングや生体材料の進歩などの技術革新の影響を受けています。研究開発への投資の増加は市場拡大をさらに後押しし、先進治療に対する規制当局の支援は大きなビジネスチャンスとなります。しかし、市場の成長には高コスト、複雑な製造工程、厳しい規制要件が課題となっています。また、新しい技術に対する患者やヘルスケアプロバイダーの認識が低いことも、市場の可能性を制限しています。

より優れた機能性のために細胞技術と合成マトリックスを組み合わせたハイブリッド製品を革新するための研究機関との提携を通じて、用途を拡大することにチャンスがあります。コスト削減戦略やスケーラブルな製造方法を模索することで、市場へのアクセスを高めることができると思われます。イノベーションはまた、モニタリング機能を強化した製品の開発や、治療中のリアルタイムフィードバックのためのデジタルヘルス技術との統合に焦点を当てることもできます。技術的な障壁と経済的な障壁の両方に対処する多面的なアプローチは、市場の大きな可能性を引き出すことができます。競合情勢は依然としてダイナミックであり、最先端の研究と卓越した規制へのコミットメントを受け入れる企業にはチャンスがあります。遺伝子技術やバイオプリンティング技術を駆使して患者固有の治療を行う個別化医療への注目は、この高度に専門化した市場における将来の成長への有望な道を示しています。

市場力学：急速に進化する組織工学による皮膚代替物市場の主要市場インサイトを公開

組織工学による皮膚代替物市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 急性および慢性創傷の増加
  • 皮膚移植の需要増加
  • 皮膚再生技術の進歩
• 市場抑制要因
  • 皮膚付属物の再生能力の限界
• 市場機会
  • ヘルスケアにおける技術の進歩と研究開発投資
  • 市場浸透を促進するための官民提携
• 市場の課題
  • 保険償還政策の欠如

ポーターの5つの力：組織工学による皮膚代替物市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：組織工学による皮膚代替物市場における外部からの影響の把握

外部マクロ環境要因は、組織工学による皮膚代替物市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析組織工学による皮膚代替物市場における競合情勢の把握

組織工学による皮膚代替物市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス組織工学による皮膚代替物市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、組織工学による皮膚代替物市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨組織工学による皮膚代替物市場における成功への道筋を描く

組織工学による皮膚代替物市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 急性および慢性創傷の罹患率の上昇
    • 皮膚移植の需要増加
    • 皮膚再生技術の進歩
  • 抑制要因
    • 皮膚付属器の再生能力が限られている
  • 機会
    • ヘルスケアにおける技術の進歩と研究開発投資
    • 市場への浸透を促進し拡大するための官民連携
  • 課題
    • 支援的な償還ポリシーの欠如
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 組織工学別皮膚代替物市場：製品別

• 生物学的
• 生合成
• 合成

第7章 組織工学別皮膚代替物市場：用途別

• 急性創傷
  • 火傷
  • 手術と外傷
• 慢性創傷
  • 糖尿病性足潰瘍
  • その他の慢性創傷
  • 褥瘡
  • 静脈性下肢潰瘍

第8章 組織工学別皮膚代替物市場：最終用途別

• 病院
• 創傷ケアセンター

第9章 南北アメリカの組織工学別皮膚代替物市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の組織工学別皮膚代替物市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの組織工学別皮膚代替物市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Bayer AG
• Beckman Coulter, Inc.
• Convatec Group PLC
• Integra LifeSciences Corporation
• Johnson & Johnson Services, Inc.
• KCI Licensing, Inc.
• Mallinckrodt PLC
• Medline Industries, Inc
• Medtronic PLC
• Merck KGaA
• MiMedx Group Inc.
• Novartis AG
• Organogenesis, Inc.
• Regenicin, Inc.
• Sanofi S.A.
• Smith & Nephew PLC
• The 3M Company
• Thermo Fisher Scientific, Inc.

LIST OF FIGURES

• FIGURE 1. TISSUE ENGINEERED SKIN SUBSTITUTES MARKET RESEARCH PROCESS
• FIGURE 2. TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. TISSUE ENGINEERED SKIN SUBSTITUTES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. TISSUE ENGINEERED SKIN SUBSTITUTES MARKET DYNAMICS
• TABLE 7. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY BIOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY BIOSYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY BURN INJURIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY SURGERY & TRAUMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY DIABETIC FOOT ULCERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY OTHER CHRONIC WOUNDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRESSURE ULCERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY VENOUS LEG ULCERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY WOUND CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 41. CANADA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. CANADA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. CANADA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 44. CANADA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 45. CANADA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 63. AUSTRALIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 68. CHINA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. CHINA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. CHINA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 71. CHINA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 72. CHINA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 73. INDIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 74. INDIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. INDIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 76. INDIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 77. INDIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 78. INDONESIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 83. JAPAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 88. MALAYSIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. MALAYSIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 93. PHILIPPINES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 94. PHILIPPINES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 98. SINGAPORE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. SINGAPORE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 103. SOUTH KOREA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 104. SOUTH KOREA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 108. TAIWAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 109. TAIWAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 113. THAILAND TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 114. THAILAND TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 118. VIETNAM TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 119. VIETNAM TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 123. EUROPE, MIDDLE EAST & AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 129. DENMARK TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 130. DENMARK TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 134. EGYPT TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 135. EGYPT TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 139. FINLAND TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 140. FINLAND TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 144. FRANCE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 145. FRANCE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 149. GERMANY TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 150. GERMANY TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 154. ISRAEL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 155. ISRAEL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 159. ITALY TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 160. ITALY TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 161. ITALY TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 162. ITALY TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 163. ITALY TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 164. NETHERLANDS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 165. NETHERLANDS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 169. NIGERIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 170. NIGERIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 174. NORWAY TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 175. NORWAY TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 179. POLAND TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 180. POLAND TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. POLAND TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 182. POLAND TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 183. POLAND TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 184. QATAR TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 185. QATAR TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 186. QATAR TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 187. QATAR TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 188. QATAR TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 189. RUSSIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 190. RUSSIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 194. SAUDI ARABIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 195. SAUDI ARABIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 204. SPAIN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 205. SPAIN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 209. SWEDEN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 210. SWEDEN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 214. SWITZERLAND TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 215. SWITZERLAND TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 219. TURKEY TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 220. TURKEY TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 224. UNITED ARAB EMIRATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 225. UNITED ARAB EMIRATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 229. UNITED KINGDOM TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 230. UNITED KINGDOM TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY ACUTE WOUNDS, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY CHRONIC WOUNDS, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 234. TISSUE ENGINEERED SKIN SUBSTITUTES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 235. TISSUE ENGINEERED SKIN SUBSTITUTES MARKET, FPNV POSITIONING MATRIX, 2023

The Tissue Engineered Skin Substitutes Market was valued at USD 1.12 billion in 2023, expected to reach USD 1.25 billion in 2024, and is projected to grow at a CAGR of 12.65%, to USD 2.58 billion by 2030.

Tissue engineered skin substitutes represent a dynamic sector within regenerative medicine, offering advanced solutions for individuals requiring skin replacement due to burns, chronic wounds, or surgical reconstruction. The scope of these substitutes includes synthetic, biosynthetic, and living skin constructs that integrate biological or synthetic materials, promoting healing and integration with the patient's tissue. The necessity for these products is driven by a growing prevalence of chronic wounds and burn injuries, an aging population, and advancements in biotechnology that enable more effective and sustainable treatments. Applications extend across medical fields, including wound care, dermatology, and plastic surgery, significantly benefiting healthcare systems by reducing recovery times and improving patient outcomes. End-use includes hospitals, burn centers, and long-term care facilities, where such substitutes can be life-saving.

Market growth is influenced by technological innovations like 3D bioprinting and biomaterial advancements, which enhance product efficacy and adaptability to individual patient needs. Increased investment in research and development further propels market expansion, while regulatory support for advanced therapies offers significant opportunities. However, market growth is challenged by high costs, complex manufacturing processes, and stringent regulatory requirements. Limited awareness among patients and healthcare providers regarding newer technologies also restricts market potential.

Opportunities lie in expanding applications through partnerships with research institutions to innovate hybrid products that combine cellular technology with synthetic matrices for better functionality. The exploration of cost-reduction strategies and scalable manufacturing could enhance market accessibility. Innovation could also focus on developing products with enhanced monitoring capabilities or integrating with digital health technologies for real-time feedback during treatment. A multi-faceted approach addressing both technical and economic barriers can unlock substantial market potential. The competitive landscape remains dynamic, with opportunities for those embracing cutting-edge research and a commitment to regulatory excellence. Focus on personalized medicine, leveraging patient-specific treatments through genetic and bioprinting technologies, represents a promising avenue for future growth in this highly specialized market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Tissue Engineered Skin Substitutes Market

The Tissue Engineered Skin Substitutes Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of acute and chronic wounds
  • Increased demand for skin grafts
  • Advances in skin regeneration technology
• Market Restraints
  • Limited ability to reproduce skin appendages
• Market Opportunities
  • Technological advancements and R&D investment in healthcare
  • Public-private alliance to promote and increase penetration in market
• Market Challenges
  • Lack of supportive reimbursement policies

Porter's Five Forces: A Strategic Tool for Navigating the Tissue Engineered Skin Substitutes Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Tissue Engineered Skin Substitutes Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Tissue Engineered Skin Substitutes Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Tissue Engineered Skin Substitutes Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Tissue Engineered Skin Substitutes Market

A detailed market share analysis in the Tissue Engineered Skin Substitutes Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Tissue Engineered Skin Substitutes Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Tissue Engineered Skin Substitutes Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Tissue Engineered Skin Substitutes Market

A strategic analysis of the Tissue Engineered Skin Substitutes Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Tissue Engineered Skin Substitutes Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Beckman Coulter, Inc., Convatec Group PLC, Integra LifeSciences Corporation, Johnson & Johnson Services, Inc., KCI Licensing, Inc., Mallinckrodt PLC, Medline Industries, Inc, Medtronic PLC, Merck KGaA, MiMedx Group Inc., Novartis AG, Organogenesis, Inc., Regenicin, Inc., Sanofi S.A., Smith & Nephew PLC, The 3M Company, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Tissue Engineered Skin Substitutes Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Biological, Biosynthetic, and Synthetic.
• Based on Application, market is studied across Acute Wounds and Chronic Wounds. The Acute Wounds is further studied across Burn Injuries and Surgery & Trauma. The Chronic Wounds is further studied across Diabetic Foot Ulcers, Other Chronic Wounds, Pressure Ulcers, and Venous Leg Ulcers.
• Based on End Use, market is studied across Hospitals and Wound Care Centers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of acute and chronic wounds
    • 5.1.1.2. Increased demand for skin grafts
    • 5.1.1.3. Advances in skin regeneration technology
  • 5.1.2. Restraints
    • 5.1.2.1. Limited ability to reproduce skin appendages
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements and R&D investment in healthcare
    • 5.1.3.2. Public-private alliance to promote and increase penetration in market
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of supportive reimbursement policies
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Tissue Engineered Skin Substitutes Market, by Product

• 6.1. Introduction
• 6.2. Biological
• 6.3. Biosynthetic
• 6.4. Synthetic

7. Tissue Engineered Skin Substitutes Market, by Application

• 7.1. Introduction
• 7.2. Acute Wounds
  • 7.2.1. Burn Injuries
  • 7.2.2. Surgery & Trauma
• 7.3. Chronic Wounds
  • 7.3.1. Diabetic Foot Ulcers
  • 7.3.2. Other Chronic Wounds
  • 7.3.3. Pressure Ulcers
  • 7.3.4. Venous Leg Ulcers

8. Tissue Engineered Skin Substitutes Market, by End Use

• 8.1. Introduction
• 8.2. Hospitals
• 8.3. Wound Care Centers

9. Americas Tissue Engineered Skin Substitutes Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Tissue Engineered Skin Substitutes Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Tissue Engineered Skin Substitutes Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Bayer AG
• 2. Beckman Coulter, Inc.
• 3. Convatec Group PLC
• 4. Integra LifeSciences Corporation
• 5. Johnson & Johnson Services, Inc.
• 6. KCI Licensing, Inc.
• 7. Mallinckrodt PLC
• 8. Medline Industries, Inc
• 9. Medtronic PLC
• 10. Merck KGaA
• 11. MiMedx Group Inc.
• 12. Novartis AG
• 13. Organogenesis, Inc.
• 14. Regenicin, Inc.
• 15. Sanofi S.A.
• 16. Smith & Nephew PLC
• 17. The 3M Company
• 18. Thermo Fisher Scientific, Inc.